BlackThorn Therapeutics Obtains $14,000,000 Series A Funding

  • Feed Type
  • Date
    1/6/2017
  • Company Name
    BlackThorn Therapeutics
  • Mailing Address
    329 Oyster Point Blvd 3rd Floor South San Francisco, CA 94080 USA
  • Company Description
    BlackThorn Therapeutics is a clinical-stage biopharmaceutical company dedicated to transforming the lives of people with neurobehavioral disorders through the discovery and development of novel, targeted treatments.
  • Website
    http://www.blackthornrx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $14,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    BlackThorn plans to use the additional funding to progress its lead clinical-stage asset, BTRX-246040, through Phase 2 clinical development, as well as to conduct additional exploratory pilot studies in targeted indications.
  • M&A Terms
  • Venture Investor
    GV
  • Venture Investor
    Biomatics Capital partners

Trending on Xconomy